Administration of Single High Dose Letrozole for Ovulation Induction
Launched by MOUNT SINAI HOSPITAL, CANADA · Mar 3, 2016
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
Pre-study screening will be conducted before the enrolment in the study, routine fertility assessment: Physical history including fertility and fertility treatment history. Laboratory tests-cycle day 3 hormonal profile (Estradiol, Luteinizing hormone, Follicular stimulating hormone, progesterone), cycle day 3 antral follicular count.
Pregnancy will be excluded by Human chorionic gonadotropin test at day 3 of the cycle, before starting the fertility treatment.
Polycystic syndrome (PCOS) patients will be defined according to Rotterdam criteria 2003.
A prospective randomized clinical trial....
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Polycystic ovary syndrome (PCOS) patients
- • BMI (body mass index) of 18-35.
- • Proved one patent fallopian tube at least
- Exclusion Criteria:
- • Women with low ovarian response (According to Bologna criteria )
- • Blocked fallopian tubes
- • Pregnancy
- • Presence of any clinically significant health problem such that treatment with letrozole or pregnancy would not be in the subject's best interest.
- • Co-administration of other anti-estrogens
- • Hypersensitivity to Letrozole .
About Mount Sinai Hospital, Canada
Mount Sinai Hospital, located in Canada, is a leading academic health institution renowned for its commitment to innovative research and high-quality patient care. As a sponsor of clinical trials, Mount Sinai Hospital leverages its extensive expertise in various medical disciplines to advance clinical knowledge and develop new therapies. The hospital collaborates with a diverse network of healthcare professionals, researchers, and institutions to conduct rigorous trials that aim to improve health outcomes and enhance the quality of life for patients. With a focus on ethical standards and patient safety, Mount Sinai Hospital is dedicated to translating scientific discoveries into effective clinical practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Patients applied
Trial Officials
Robert Casper, MD
Principal Investigator
University of Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials